Journal of Neuro-Oncology

, Volume 26, Issue 2, pp 103–110 | Cite as

Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release

  • Kwame G. Buahin
  • Henry Brem


Interstitial chemotherapy with controlled release polymers is a clinical adjunct in the management of malignant gliomas. The need for polymer to release the chemotherapeutic drug rather than simply injecting the drug into the tumor warrants further investigation. Therefore, we compared the effects of direct intralesional injection of carmustine (BCNU) and 4-hydroperoxycyclophosphamide (4HC) into the rat brain tumor bed with those from the same agents delivered via controlled release polymers implanted intracranially. Treatment was initiated on the fifth day after intracranial implantation of 9L gliosarcoma into male rats; two doses of each drug were injected intratumorally, representing either the amount of drug typically releasedin vivo from polymer during the first 24 h, or the maximal drug loaded on each polymer. Control rats were treated with empty polymers. We found that the median lifespan was extended in the groups of rats treated with intratumoral injection of BCNU (23% and 36% for 1 mg and 2 mg doses), and 271% with BCNU-impregnated polymer. Similar results were found with intratumoral 4HC (21% and 36% for 0.1 mg and 2 mg injection doses), and 121% with 4HC-impregnated polymer. Overall survival after intraneoplastic injections, however, was not statistically significantly different from that of control rats (p > 0.05). Furthermore, improvement in survival was not consistent, and some animals subjected to 4HC injection died early in the course of treatment. Polymeric treatment resulted in statistically significant prolongation of survival, compared to control rats (p < 0.001 for both BCNU and 4HC). We conclude that direct intralesional injection of BCNU and 4HC is less effective than controlled release via polymers for the treatment of 9L gliosarcoma in the rat model.

Key words

interstitial chemotherapy rat 9L glioma 4-hydroperoxycyclophosphamide BCNU polymeric delivery 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Phillips PC: Antineoplastic drug resistance in brain tumors. Neurol Clin 9 (2): 383–404, 1991PubMedGoogle Scholar
  2. 2.
    Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30: 907–911, 1980PubMedGoogle Scholar
  3. 3.
    Tamargo RJ, Brem H: Drug delivery to the central nervous system: A review. Neurosurgery Quarterly 2 (4): 259–279, 1992Google Scholar
  4. 4.
    Kimler BF, Vats TS, Morantz RA, Henderson SD: Response of the 9L rat brain tumor to combination treatment with radiation and bleomycin. Int J Radiat Oncol Biol Phys 7: 1069–1074, 1981PubMedGoogle Scholar
  5. 5.
    Kimler BF, Martin DF, Evans RG, Morantz RA, Vats TS: Combination of radiation therapy and intracranial bleomycin in the 9L rat brain tumor model. Int J Radiat Oncol Biol Phys 18: 1115–1121, 1990PubMedGoogle Scholar
  6. 6.
    Kimler BF, Liu C, Evans RG, Morantz RA: Intracerebral chemotherapy in the 9L rat brain tumor model. J Neuro-Oncol 14 (3): 191–200, 1992Google Scholar
  7. 7.
    Zeller WJ, Bauer S, Remmele T, Wowra B, Sturm V, Stricker H: Interstitial chemotherapy of experimental gliomas. Cancer Treatment Rev 17 (2–3): 183–189, 1990Google Scholar
  8. 8.
    Tator CH, Wassenaar W: Intraneoplastic injection of methotrexate for experimental brain-tumor chemotherapy. J Neurosurg 46: 165–174, 1977PubMedGoogle Scholar
  9. 9.
    Tator CH: Intraneoplastic injection of CCNU for experimental brain tumor chemotherapy. Surg Neurol 7: 73–77, 1977PubMedGoogle Scholar
  10. 10.
    Tator CH, Wassenaar W, Day A, So WS: Therapy of an experimental glioma with systemic or intraneoplastic methotrexate or radiation. J Neurosurg 46: 175–184, 1977PubMedGoogle Scholar
  11. 11.
    Penn RD, Kroin JS, Harris JE, Chiu KM, Braun DP: Chronic intratumoral chemotherapy of a rat tumor with cisplatin and fluorouracil. Appl Neurophysiol 46: 240–244, 1983PubMedGoogle Scholar
  12. 12.
    Firth G, Oliver AS, McKeran RO: Studies on the intracerebral injection of bleomycin free and entrapped within liposomes in the rat. J Neurol Neurosurg Psychiat 47: 585–589, 1984PubMedGoogle Scholar
  13. 13.
    Oliver AS, Firth G, McKeran RO: Studies on the intracerebral injection of vincristine free and entrapped within liposomes in the rat. J Neurol Sci 68: 25–30, 1985PubMedGoogle Scholar
  14. 14.
    Tomita T: Interstitial chemotherapy for brain tumors: review. J Neuro-Oncol 10: 57–74, 1991Google Scholar
  15. 15.
    Vats TS, Morantz RA, Wood GW, Tilzer S: Study of effectiveness of bleomycin in rat brain tumor model intravenously and intracerebrally. Int J Radiat Oncol Biol Phys 5: 1527–1529, 1979PubMedGoogle Scholar
  16. 16.
    Weiss SR, Raskind R: Treatment of malignant brain tumors by local methotrexate. A preliminary report. Int Surg 51: 149–155, 1969PubMedGoogle Scholar
  17. 17.
    Bosch DA, Hindmarsch TH, Larsson ST, Baclund EO: Intraneoplastic administration of bleomycin in intracerebral glioma: A pilot study. Acta Neurochir (Wien) 30 (suppl): 441–444, 1980Google Scholar
  18. 18.
    Bouvier G, Penn RD, Kroin JS, Beique RA, Guerard M-J, Lesage J: Stereotactic administration of intratumoral chronic chemotherapy of recurrent malignant gliomas. Appl Neurophysiol 50: 223–226, 1987PubMedGoogle Scholar
  19. 19.
    Garfield J, Dyan AD: Postoperative intracavitary chemotherapy of malignant gliomas. A preliminary study using methotrexate. J Neurosurg 39: 315–322, 1973PubMedGoogle Scholar
  20. 20.
    Garfield J, Dayan AD, Weller RO: Postoperative intracavitary chemotherapy of malignant supratentorial astrocytomas using BCNU. Clin Oncol 1: 213–222, 1975PubMedGoogle Scholar
  21. 21.
    Kroin JS, Penn RD: Intracerebral chemotherapy: chronic microinfusion of cisplatin. Neurosurgery 10 (3): 349–354, 1982PubMedGoogle Scholar
  22. 22.
    Ringkjob R: Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta Neurol Scand 44: 318–322, 1968PubMedGoogle Scholar
  23. 23.
    Brem H: Polymers to treat brain tumours. Biomaterials 11: 699–701, 1990PubMedGoogle Scholar
  24. 24.
    Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H: Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res 53: 329–333, 1993PubMedGoogle Scholar
  25. 25.
    Brem H, Mahaley MS, Vick NA, Black KL, Schold JSC, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, Kenealy JN: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74: 441–446, 1991PubMedGoogle Scholar
  26. 26.
    Buahin KG, Judy KD, Hartke C, Domb A, Maniar M, Colvin OM, Brem H: Controlled release of 4-hydroperoxycyclophosphamide from the fatty acid dimer-sebacic acid copolymer. Polymers for Advanced Tech 3 (6): 311–316, 1992Google Scholar
  27. 27.
    Yang MB, Tamargo RJ, Brem H: Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res 49: 5103–5107, 1989PubMedGoogle Scholar
  28. 28.
    Tamargo RJ, Myseros JS, Brem H: Growth inhibition of the 9L gliosarcoma by the local sustained release of BCNU: A comparison of systemic versus regional chemotherapy. (Abstract): American Association of Neurological Surgeons, Toronto, Canada: 212–214, 1988Google Scholar
  29. 29.
    Tamargo RJ, Epstein JI, Yang MB, Pinn ML, Chasin M, Brem H: Interstitial versus systemic chemotherapy of the intracranial 9L gliosarcoma: Controlled-release polymers for local therapy. J Neurosurg 70: 311A, 1989Google Scholar
  30. 30.
    Judy KD, Olivi AO, Buahin KG, Domb A, Epstein JI, Colvin OM, Brem H: Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J Neurosurg 82: 481–486, 1995PubMedGoogle Scholar
  31. 31.
    Domb AJ, Maniar M: Absorbable biopolymers derived from dimer fatty acids. J Polymer Sci 31: 1275–1285, 1993Google Scholar
  32. 32.
    Domb AJ, Langer R: Polyanhydrides. I. Preparation of high molecular weight polyanhydrides. J Polymer Sci 25: 3373–3386, 1987Google Scholar
  33. 33.
    Leong KW, Brott BC, Langer R: Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J Biomed Mat Res 19: 941–955, 1985Google Scholar
  34. 34.
    Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, Brem H: The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 76 (4): 640–647, 1992PubMedGoogle Scholar
  35. 35.
    Chasin M, Domb A, Ron E, Mathiowitz E, Langer R, Leong K, Laurencin C, Brem H, Grossman S: Polyanhydrides as drug delivery systems. In: Chasin M, Langer R (eds) Biodegradable Polymers as Drug Delivery Systems. Marcel-Dekker, New York, 1990, pp 43–70Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Kwame G. Buahin
    • 1
  • Henry Brem
    • 1
    • 2
  1. 1.Department of NeurosurgeryJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of OncologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations